Guardians of Health
CELLIMA TALKS V – Ion Channels in Drug Discovery
CELLIMA TALKS V
How Ion Channels Drive Early Drug Discovery
Thomas Müller shares insights from more than 30 years of ion channel research, spanning screening technology, electrophysiology, and optogenetics.
He began his scientific career in Heidelberg and Glasgow and is now Head of Cellular High-Throughput Screening at Bayer, where he shapes scientific strategy and evaluation of early pharmacological hits.
“Ion channels are essential regulators of cellular function — and a critical target class in modern drug discovery.”
Thomas Müller
From Molecular Physiology to HTS Workflows
In this conversation, Thomas explains:
why ion channels are central to neuroscience, cardiology, and pain research
how high-throughput screening (HTS) has accelerated hit identification
the benefits and limitations of electrophysiology and optogenetics
where innovation is emerging in automated functional assays
These insights provide a clear picture of how technology and biology converge to enable better therapeutic decisions.
Watch the Interview
🎥 Full Episode — CELLIMA TALKS V
German & English versions available:
▶️ Watch on YouTube (German)
▶️ Watch on YouTube (English dubbed)
🎧 Listen via Apple Podcasts
About the Speaker: Thomas Müller
Head of Cellular HTS, Bayer
Expertise: ion channels, phenotypic screening, functional assays
30+ years in academic and pharmaceutical research
Target Audience
Researchers in:
Pharmacology
Neuroscience
Drug Screening Technologies
Cardiovascular & Pain Research
